Alfasigma acquires Lumeblue™ (Methylene Blue MMX) rights for EU distribution, consolidating its Gastro-Intestinal portfolio
Cosmo Pharmaceuticals will receive a €4m upfront payment Alfasigma plus double digit royalties
Cosmo Pharmaceuticals will receive a €4m upfront payment Alfasigma plus double digit royalties